Community Research and Development Information Service - CORDIS

ERC

LIPIDOLIV Report Summary

Project ID: 336629
Funded under: FP7-IDEAS-ERC
Country: France

Mid-Term Report Summary - LIPIDOLIV (Role of the transcription factor ChREBP and its associated proteins in the development and progression of NAFLD.)

The research of our team aims to better understand how regulatory proteins, including specific transcription factors and transcriptional coregulators, act as sensors for molecules of nutritional, metabolic or pharmacological origin, and translate them into altered patterns of gene expression affecting metabolic function during metabolic diseases and cancer. We specifically aim to determine how nutrients, such as glucose, trough the regulation of the transcription factor ChREBP (Carbohydrate Responsive Element Binding Protein) favor the development and progression of Non Alcoholic Fatty Liver Disease (NAFLD), which usually refers to the build-up of neutral lipids within the hepatocytes and which is emerging as the most common chronic liver disease in western countries. Indeed, the spectrum of NAFLD ranges from simple hepatic steatosis with benign prognosis, to more severe forms including nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). Today it seems that defining types of cells and subcellular compartments in which changes in levels of specific lipid species occur may identify new avenues for potential prevention or treatment of NAFLD. In this regard, our team studies the complete cellular and molecular spectrum of these aspects.

Overall, the aim of our research program is to provide a better understanding of the role of the transcription factor ChREBP and its associated proteins in the development and progression of NAFLD to NASH and HCC. It will specifically decipher the function of ChREBP in hepatocytes and immune cells and will provide important information on the molecular events leading to the development of inflammation, insulin resistance and oxidative stress during the disease progression. Since many of these signaling and transcriptional events contribute to the pathogenesis of common metabolic disorders (e.g. obesity, type 2 diabetes), our research paved the way for novel preventive and therapeutic strategies for these diseases.

Contact

LYDDIE LAALAND, (GESTIONNAIRE DES RESSOURCES EXTERNES)
Tel.: +33 1 40 78 49 35
Fax: +33 1 40 78 49 98
E-mail
Record Number: 189640 / Last updated on: 2016-10-13